235 related articles for article (PubMed ID: 23624363)
1. The malaria vaccine candidate GMZ2 elicits functional antibodies in individuals from malaria endemic and non-endemic areas.
Jepsen MP; Jogdand PS; Singh SK; Esen M; Christiansen M; Issifou S; Hounkpatin AB; Ateba-Ngoa U; Kremsner PG; Dziegiel MH; Olesen-Larsen S; Jepsen S; Mordmüller B; Theisen M
J Infect Dis; 2013 Aug; 208(3):479-88. PubMed ID: 23624363
[TBL] [Abstract][Full Text] [Related]
2. Immunogenicity of a virosomally-formulated Plasmodium falciparum GLURP-MSP3 chimeric protein-based malaria vaccine candidate in comparison to adjuvanted formulations.
Tamborrini M; Stoffel SA; Westerfeld N; Amacker M; Theisen M; Zurbriggen R; Pluschke G
Malar J; 2011 Dec; 10():359. PubMed ID: 22166048
[TBL] [Abstract][Full Text] [Related]
3. Humoral immune response to Plasmodium falciparum vaccine candidate GMZ2 and its components in populations naturally exposed to seasonal malaria in Ethiopia.
Mamo H; Esen M; Ajua A; Theisen M; Mordmüller B; Petros B
Malar J; 2013 Feb; 12():51. PubMed ID: 23383869
[TBL] [Abstract][Full Text] [Related]
4. A phase 2b randomized, controlled trial of the efficacy of the GMZ2 malaria vaccine in African children.
Sirima SB; Mordmüller B; Milligan P; Ngoa UA; Kironde F; Atuguba F; Tiono AB; Issifou S; Kaddumukasa M; Bangre O; Flach C; Christiansen M; Bang P; Chilengi R; Jepsen S; Kremsner PG; Theisen M;
Vaccine; 2016 Aug; 34(38):4536-4542. PubMed ID: 27477844
[TBL] [Abstract][Full Text] [Related]
5. A synthetic TLR4 agonist formulated in an emulsion enhances humoral and Type 1 cellular immune responses against GMZ2--a GLURP-MSP3 fusion protein malaria vaccine candidate.
Lousada-Dietrich S; Jogdand PS; Jepsen S; Pinto VV; Ditlev SB; Christiansen M; Larsen SO; Fox CB; Raman VS; Howard RF; Vedvick TS; Ireton G; Carter D; Reed SG; Theisen M
Vaccine; 2011 Apr; 29(17):3284-92. PubMed ID: 21349366
[TBL] [Abstract][Full Text] [Related]
6. Effect of hookworm infection and anthelmintic treatment on naturally acquired antibody responses against the GMZ2 malaria vaccine candidate and constituent antigens.
Amoani B; Gyan B; Sakyi SA; Abu EK; Nuvor SV; Barnes P; Sarkodie-Addo T; Ahenkorah B; Sewor C; Dwomoh D; Theisen M; Cappello M; Wilson MD; Adu B
BMC Infect Dis; 2021 Apr; 21(1):332. PubMed ID: 33832450
[TBL] [Abstract][Full Text] [Related]
7. Controlled Human Malaria Infection of Healthy Adults With Lifelong Malaria Exposure to Assess Safety, Immunogenicity, and Efficacy of the Asexual Blood Stage Malaria Vaccine Candidate GMZ2.
Dejon-Agobe JC; Ateba-Ngoa U; Lalremruata A; Homoet A; Engelhorn J; Nouatin OP; Edoa JR; Fernandes JF; Esen M; Mouwenda YD; Betouke Ongwe EM; Massinga-Loembe M; Hoffman SL; Sim BKL; Theisen M; Kremsner PG; Adegnika AA; Lell B; Mordmüller B
Clin Infect Dis; 2019 Sep; 69(8):1377-1384. PubMed ID: 30561539
[TBL] [Abstract][Full Text] [Related]
8. Naturally acquired antibody response to a Plasmodium falciparum chimeric vaccine candidate GMZ2.6c and its components (MSP-3, GLURP, and Pfs48/45) in individuals living in Brazilian malaria-endemic areas.
Baptista BO; de Souza ABL; Riccio EKP; Bianco-Junior C; Totino PRR; Martins da Silva JH; Theisen M; Singh SK; Amoah LE; Ribeiro-Alves M; Souza RM; Lima-Junior JC; Daniel-Ribeiro CT; Pratt-Riccio LR
Malar J; 2022 Jan; 21(1):6. PubMed ID: 34983540
[TBL] [Abstract][Full Text] [Related]
9. Safety and immunogenicity of GMZ2 - a MSP3-GLURP fusion protein malaria vaccine candidate.
Esen M; Kremsner PG; Schleucher R; Gässler M; Imoukhuede EB; Imbault N; Leroy O; Jepsen S; Knudsen BW; Schumm M; Knobloch J; Theisen M; Mordmüller B
Vaccine; 2009 Nov; 27(49):6862-8. PubMed ID: 19755144
[TBL] [Abstract][Full Text] [Related]
10. Immunogenicity of a recombinant malaria vaccine candidate, domain I+II of AMA-1 ectodomain, from Indian P. falciparum alleles.
Lalitha PV; Biswas S; Pillai CR; Saxena RK
Vaccine; 2008 Aug; 26(35):4526-35. PubMed ID: 18590786
[TBL] [Abstract][Full Text] [Related]
11. A randomized controlled phase Ib trial of the malaria vaccine candidate GMZ2 in African children.
Bélard S; Issifou S; Hounkpatin AB; Schaumburg F; Ngoa UA; Esen M; Fendel R; de Salazar PM; Mürbeth RE; Milligan P; Imbault N; Imoukhuede EB; Theisen M; Jepsen S; Noor RA; Okech B; Kremsner PG; Mordmüller B
PLoS One; 2011; 6(7):e22525. PubMed ID: 21829466
[TBL] [Abstract][Full Text] [Related]
12. Glutamate-rich protein (GLURP) induces antibodies that inhibit in vitro growth of Plasmodium falciparum in a phase 1 malaria vaccine trial.
Hermsen CC; Verhage DF; Telgt DS; Teelen K; Bousema JT; Roestenberg M; Bolad A; Berzins K; Corradin G; Leroy O; Theisen M; Sauerwein RW
Vaccine; 2007 Apr; 25(15):2930-40. PubMed ID: 16914240
[TBL] [Abstract][Full Text] [Related]
13. Merozoite surface protein 3 and protection against malaria in Aotus nancymai monkeys.
Hisaeda H; Saul A; Reece JJ; Kennedy MC; Long CA; Miller LH; Stowers AW
J Infect Dis; 2002 Mar; 185(5):657-64. PubMed ID: 11865423
[TBL] [Abstract][Full Text] [Related]
14. Expression, Purification and Characterization of GMZ2'.10C, a Complex Disulphide-Bonded Fusion Protein Vaccine Candidate against the Asexual and Sexual Life-Stages of the Malaria-Causing Plasmodium falciparum Parasite.
Mistarz UH; Singh SK; Nguyen TTTN; Roeffen W; Yang F; Lissau C; Madsen SM; Vrang A; Tiendrebeogo RW; Kana IH; Sauerwein RW; Theisen M; Rand KD
Pharm Res; 2017 Sep; 34(9):1970-1983. PubMed ID: 28646324
[TBL] [Abstract][Full Text] [Related]
15. Synthetic TLR4 agonists enhance functional antibodies and CD4+ T-cell responses against the Plasmodium falciparum GMZ2.6C multi-stage vaccine antigen.
Baldwin SL; Roeffen W; Singh SK; Tiendrebeogo RW; Christiansen M; Beebe E; Carter D; Fox CB; Howard RF; Reed SG; Sauerwein R; Theisen M
Vaccine; 2016 Apr; 34(19):2207-15. PubMed ID: 26994314
[TBL] [Abstract][Full Text] [Related]
16. Exploratory analysis of the effect of helminth infection on the immunogenicity and efficacy of the asexual blood-stage malaria vaccine candidate GMZ2.
Nouatin O; Mengue JB; Dejon-Agobé JC; Fendel R; Ibáñez J; Ngoa UA; Edoa JR; Adégbité BR; Honkpéhédji YJ; Zinsou JF; Hounkpatin AB; Moutairou K; Homoet A; Esen M; Kreidenweiss A; Hoffman SL; Theisen M; Luty AJF; Lell B; Agnandji ST; Mombo-Ngoma G; Ramharter M; Kremsner P; Mordmüller B; Adegnika AA
PLoS Negl Trop Dis; 2021 Jun; 15(6):e0009361. PubMed ID: 34061838
[TBL] [Abstract][Full Text] [Related]
17. The GMZ2 malaria vaccine: from concept to efficacy in humans.
Theisen M; Adu B; Mordmüller B; Singh S
Expert Rev Vaccines; 2017 Sep; 16(9):907-917. PubMed ID: 28699823
[TBL] [Abstract][Full Text] [Related]
18. Safety and immunogenicity of the malaria vaccine candidate GMZ2 in malaria-exposed, adult individuals from Lambaréné, Gabon.
Mordmüller B; Szywon K; Greutelaers B; Esen M; Mewono L; Treut C; Mürbeth RE; Chilengi R; Noor R; Kilama WL; Imoukhuede EB; Imbault N; Leroy O; Theisen M; Jepsen S; Milligan P; Fendel R; Kremsner PG; Issifou S
Vaccine; 2010 Sep; 28(41):6698-703. PubMed ID: 20696154
[TBL] [Abstract][Full Text] [Related]
19. Immunogenic properties of a recombinant fusion protein containing the C-terminal 19 kDa of Plasmodium falciparum merozoite surface protein-1 and the innate immunity agonist FliC flagellin of Salmonella typhimurium.
Bargieri DY; Leite JA; Lopes SC; Sbrogio-Almeida ME; Braga CJ; Ferreira LC; Soares IS; Costa FT; Rodrigues MM
Vaccine; 2010 Apr; 28(16):2818-26. PubMed ID: 20170765
[TBL] [Abstract][Full Text] [Related]
20. Recombinant Liver Stage Antigen-1 (LSA-1) formulated with AS01 or AS02 is safe, elicits high titer antibody and induces IFN-gamma/IL-2 CD4+ T cells but does not protect against experimental Plasmodium falciparum infection.
Cummings JF; Spring MD; Schwenk RJ; Ockenhouse CF; Kester KE; Polhemus ME; Walsh DS; Yoon IK; Prosperi C; Juompan LY; Lanar DE; Krzych U; Hall BT; Ware LA; Stewart VA; Williams J; Dowler M; Nielsen RK; Hillier CJ; Giersing BK; Dubovsky F; Malkin E; Tucker K; Dubois MC; Cohen JD; Ballou WR; Heppner DG
Vaccine; 2010 Jul; 28(31):5135-44. PubMed ID: 19737527
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
